About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. Two ...

StockNews.com cut shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) from a hold rating to a sell rating in a report ...

Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, and it can shapeshift in unpredictable ways to evade treatment.

Hoth Therapeutics Inc., a biopharmaceutical company committed to developing innovative therapies for unmet medical needs, has collaborated with OnTargetx R&D Inc. to accelerate research for its cancer ...

As part of its continued commitment to developing next-generation cancer therapeutics, Ocean Biomedical is initiating ...

New blinded preliminary BRTX-100 data described this past Saturday at prestigious "2025 Winners in Industry Innovations in MSK Health” presentation - - Among other positive preliminary data analyses, ...